Tejaswini Kulkarni, MD, MPH
Dr. Kulkarni received her medical training and internship at Bangalore Medical College and Research Institute following which she obtained a Masters in Public Health at Harvard T.H. Chan School of Public Health. She completed a residency in Internal Medicine at Wayne State University 2013. Dr. Kulkarni then completed a clinical and research fellowship in the Division of Pulmonary, Allergy and Critical Care medicine at UAB in 2016 and was appointed as faculty within this Division. Dr. Kulkarni currently serves as the Director of Interstitial Lung Disease Program at UAB and champions efforts to provide quality clinical care to patients with interstitial lung diseases at her center. As a member of the steering committee of ILD network at American College of Chest Physicians, she strives to promote education for early diagnosis and quality treatment of these patients within the community as well. Dr. Kulkarni is currently principal/co-investigator on clinical trials studying new therapeutics for ILD and her research focuses on developing imaging biomarkers to prognosticate and assess response to therapy among these patients.
Financial relationships
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:Boehringer IngelheimDate added:01/14/2025Date updated:01/14/2025
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:PuretechDate added:01/14/2025Date updated:01/14/2025
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:United TherapeuticsDate added:01/14/2025Date updated:01/14/2025
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:AileronDate added:01/14/2025Date updated:01/14/2025
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:AvalynDate added:01/14/2025Date updated:01/14/2025
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:TempusDate added:01/14/2025Date updated:01/14/2025
-
Attribution:SelfType of financial relationship:Consulting FeeIneligible company:VicoreDate added:01/14/2025Date updated:01/14/2025